Skip to main content

Table 1 Details of the 21-day interval chemotherapy regimen

From: Evaluating the analgesic effect and advantage of transcutaneous electrical acupoint stimulation combined with opioid drugs for moderate to severe cancer-related pain: a study protocol for a randomized controlled trial

Chemotherapy regimen

Drugs

Dosage

Administration route

Medication time

Combined chemotherapy

 NP

Navelbine

25 mg/m2

i.v.

D1, D8

Cis-platinum

80 mg/m2

i.v.

D1

 TP

Paclitaxel

135~175 mg/m2

i.v.

D1

Cis-platinum

75 mg/m2

i.v.

D1

or Carboplatin

AUC = 5–6 mg/m2

i.v.

D1

 GP

Gemcitabine

1250 mg/m2

i.v.

D1, D8

Cis-platinum

75 mg/m2

i.v.

D1

or Carboplatin

AUC = 5–6 mg/m2

i.v.

D1

 DP

Docetaxel

75 mg/m2

i.v.

D1

Cis-platinum

75 mg/m2

i.v.

D1

or Carboplatin

AUC = 5–6 mg/m2

i.v.

D1

 PC

Pemetrexed

500 mg/m2

i.v.

D1

Cis-platinum

75 mg/m2

i.v.

D1

or Carboplatin

AUC = 5–6 mg/m2

i.v.

D1

 EP

Etoposide

100 mg/m2

i.v.

D1–3

Cis-platinum

80 mg/m2

i.v.

D1

or Carboplatin

AUC = 5–6 mg/m2

i.v.

D1

 EP

Etoposide

120 mg/m2

i.v.

D1–3

Cis-platinum

60 mg/m2

i.v.

D1

 IP

Irinotecan

65 mg/m2

i.v.

D1, D8

Cis-platinum

30 mg/m2

i.v.

D1, D8

 AP

Amrubicin

40 mg/m2

i.v.

D1–3

Cis-platinum

60 mg/m2

i.v.

D1

 XT

Docetaxel

75 mg/m2

i.v.

D1

Capecitabine

950 mg/m2

p.o.

D1–14

 GT

Paclitaxel

175 mg/m2

i.v.

D1

Gemcitabine

1000~1250 mg/m2

i.v.

D1, D8

 TC

Docetaxel

75 mg/m2

i.v.

D1

Cyclophosphamide

600 mg/m2

i.v.

D1

 TAC

Docetaxel

75 mg/m2

i.v.

D1

Doxorubicin

50 mg/m2

i.v.

D1

Cyclophosphamide

500 mg/m2

i.v.

D1

Single-agent chemotherapy

 Doxorubicin

Doxorubicin

75 mg/m2

i.v.

D1

 Paclitaxel

Paclitaxel

175 mg/m2

i.v.

D1

 Docetaxel

Docetaxel

80 mg/m2

i.v.

D1

 Capecitabine

Capecitabine

1000–1250 mg/m2

p.o.

D1–14

 Herceptin

Herceptin

6 mg/kg

i.v.

D21

  1. i.v. intravenous injection, p.o. per os (oral administration)